ArticleFrontiers in medicine2026
Biologics and biosimilars medication errors in Saudi Arabia: a nationwide retrospective observational real-world study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deviations from recommended use of liposomal bupivacaine: a real-world pharmacovigilance study using the FAERS database.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Saudi Arabia, the Ministry of Health reported 71, 332 errors from 2018 to 2019. Biologics and biosimilars are safe treatment options for various medical conditions; however, safety concerns remain. Immunogenicity and unique brand names can cause adverse reactions, and the ability to predict immune responses is limited. This study aims to determine the number and characteristics of medication errors associated with biological and biosimilar medications in Saudi Arabia from 2020 to 2023. Methods: A retrospective observational real-world study was conducted to analyze the number of biologic and biosimilar medication errors reported to the MOH, Saudi Arabia, from 2020 to 2023 using an electronic database as a data source. Categorical data were summarized as frequency and percentage. All analyses were performed using Microsoft Excel. Results: A total of 63,817 medication error reports related to biologics and biosimilars were identified. The majority occurred during the prescribing phase (76-79%) and were classified as non-harmful (Category B, ≈70%). Pharmacists were the leading reporters (87%), underlining their central role in patient safety. Adults (>18 years) represented the most affected demographic group (≈70%). Insulin and anticoagulants (enoxaparin and heparin) together accounted for the highest proportion of errors, highlighting these agents as key targets for safety interventions. Conclusion: This study offers a comprehensive national evaluation of medication errors associated with biologic and biosimilar products reported to the Saudi Ministry of Health between 2020 and 2023. High-alert medications, particularly insulin and anticoagulants, consistently ranked among the top error-related agents, highlighting the need for targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.